A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma

NCT01164007 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Bevacizumab
DRUG: Dacarbazine

Sponsor

Hoffmann-La Roche